Management and Treatment for Patients with Beta-2 Glycoprotein Antibodies

Diagnostic Criteria and Classification

Beta-2 glycoprotein I antibodies are one of the laboratory criteria for antiphospholipid syndrome, along with lupus anticoagulant and anticardiolipin antibodies, as defined by the International Society on Thrombosis and Haemostasis 1
Positive aβ2GPI is defined as IgG/IgM isotype in plasma or serum present at levels >99th percentile of normal controls, measured by solid phase assays, according to the Journal of Thrombosis and Haemostasis 1
For diagnosis of APS, antibodies should be positive on two or more occasions at least 12 weeks apart, as recommended by the International Society on Thrombosis and Haemostasis 1

Patients with multiple positive antiphospholipid antibodies are at particularly high risk for thrombosis or pregnancy morbidity, as stated by the International Society on Thrombosis and Haemostasis 1

For asymptomatic patients with persistent aβ2GPI, the decision for prophylactic therapy should be based on additional risk factors, according to the American College of Rheumatology 2
Low-dose aspirin may be considered for primary thrombosis prevention in asymptomatic patients with persistent positive aβ2GPI, although evidence for efficacy is limited, as reported by the American Heart Association 3
Hydroxychloroquine should be considered, especially in patients with underlying systemic lupus erythematosus, as recommended by the European League Against Rheumatism 4

Women with positive aβ2GPI who are pregnant should be managed by a multidisciplinary team, according to the European League Against Rheumatism 4
For women with obstetric APS, low-molecular-weight heparin and low-dose aspirin are recommended during pregnancy, as stated by the European League Against Rheumatism 4
Combined hormonal contraceptives are contraindicated in women with positive aβ2GPI due to increased thrombosis risk, as recommended by the American College of Rheumatology 2

Aggressive management of traditional cardiovascular risk factors is essential in patients with aβ2GPI antibodies, as reported by the American Heart Association 3

Regular clinical follow-up to assess for signs/symptoms of thrombosis is necessary, as recommended by the International Society on Thrombosis and Haemostasis 1
Laboratory results need to be reviewed and interpreted in collaboration between a clinical pathologist and a clinician skilled at interpreting the data, according to the International Society on Thrombosis and Haemostasis 1

Lower-titer aβ2GPI that doesn't meet laboratory classification criteria may still confer some thrombotic risk, but this is difficult to quantify, as stated by the American College of Rheumatology 2
Antiphospholipid antibody testing in patients under anticoagulation therapy may cause erroneous results, as reported by the International Society on Thrombosis and Haemostasis 1
Testing for antiphospholipid antibodies should include comprehensive evaluation as triple-positive patients have the highest risk, according to the International Society on Thrombosis and Haemostasis 1